RecruitingNot applicableNCT06801119

Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs)

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shenzhen MagicRNA Biotechnology Co., Ltd
Principal Investigator
Zhu Chen, MD
The First Affiliated Hospital of University of Science and Technology of China
Intervention
HN2301 injection(drug)
Enrollment
30 enrolled
Eligibility
18-69 years · All sexes
Timeline
20252026

Study locations (1)

Collaborators

The First Affiliated Hospital of University of Science and Technology of China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06801119 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis

← Back to all trials